<DOC>
	<DOCNO>NCT01897038</DOCNO>
	<brief_summary>This multicenter , open-label study evaluate maximum tolerate dose ( MTD ) dose-limiting toxicity onartuzumab single agent combination sorafenib participant advance hepatocellular carcinoma . Participants Cohort 1 receive onartuzumab single agent Day 1 21-day cycle . Participants Cohorts 2 3 receive onartuzumab Day 1 21-day cycle combination sorafenib 400 mg orally daily twice daily . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetics Study Onartuzumab Single Agent Combination With Sorafenib Participants With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Cytologically histologically confirm diagnosis hepatocellular carcinoma ( HCC ) Advanced metastatic disease Not candidate curative treatment ( , resection , transplantation ) ChildPugh class A liver function Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Life expectancy great ( &gt; ) 3 month For participant receive prior adjuvant chemotherapy , treatmentfree interval least 6 month last chemotherapy cycle Cycle 1 Day 1 Prior surgery local therapy within 4 week prior Cycle 1 Day 1 , exception palliative radiation therapy bone Brain metastasis spinal cord compression definitively treat surgery and/or radiation Granulocyte count le ( &lt; ) 1500 per cubic millimeter ( mm^3 ) , platelet count &lt; 75,000/mm^3 , hemoglobin &lt; 8 gram per deciliter ( g/dL ) within 7 day prior Cycle 1 Day 1 Total bilirubin great ( &gt; ) 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) serum glutamicoxaloacetic transaminase ( SGOT ) , Alanine transaminase ( ALT ) serum glutamicpyruvic transaminase ( SGPT ) , alkaline phosphatase ( ALP ) &gt; 5 × ULN Serum creatinine &gt; 1.5 × ULN creatinine clearance &lt; 60 cubic centimeter per minute ( cc/min ) CockcroftGault formula Significant history cardiac disease within 6 month prior Cycle 1 Day 1 , myocardial infarction within previous year , current cardiac ventricular arrhythmia require medication Serious active infection , serious underlie medical condition would impair ability participant receive protocol treatment , exception hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection Known active infection human immunodeficiency virus ( HIV ) know HIVseropositivity Inability take oral medication untreated malabsorption syndrome Pregnant lactate woman History transplantation include organ , bone marrow transplantation , peripheral blood stem cell transplantation exception corneal transplantation Active bleeding diathesis ( include active esophageal varix ) tumor rupture within 8 week prior Cycle 1 Day1 successfully treat Uncontrolled hypertension Treatment investigational drug within 4 week Cycle 1 Day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>